Core Viewpoint - MoonLake Immunotherapeutics is facing a securities fraud class action lawsuit due to alleged misrepresentations regarding its clinical data and the efficacy of its investigational drug sonelokimab [1][3][4]. Group 1: Lawsuit Details - A lawsuit has been filed against MoonLake and certain senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][3]. - Investors have until December 15, 2025, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Southern District of New York [3]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational drug sonelokimab [4]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated a higher clinical response for patients, suggesting a competitive advantage over traditional monoclonal antibody treatments [5]. Group 3: Allegations and Impact - The lawsuit alleges that the clinical data and Nanobody structure of sonelokimab did not provide a superior clinical benefit compared to competitors, raising doubts about the drug's regulatory approval and commercial viability [6]. - Following the announcement of disappointing results from the Phase 3 VELA trials, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share within a few days [7].

Core Viewpoint - Rosen Law Firm is reminding purchasers of MoonLake Immunotherapeutics common stock of the lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the class period from March 10, 2024, to September 29, 2025 [1]. Group 1: Class Action Details - Investors who purchased MoonLake common stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit a form online or contact the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the court by December 15, 2025, to represent other class members in the litigation [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [4]. Group 3: Case Allegations - The complaint alleges that during the class period, MoonLake made false and misleading statements regarding its product SLK, particularly in comparison to monoclonal antibodies like BIMZELX [5]. - Specific claims include that SLK and BIMZELX target the same inflammatory cytokines, and that SLK's unique structure does not provide a clinical advantage over traditional monoclonal antibodies [5].

Core Viewpoint - A securities class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging that the company and its executives made materially false and misleading statements about the clinical prospects of their drug candidate, sonelokimab (SLK), leading to a nearly 90% stock crash following disappointing Phase 3 trial results [2][3][4]. Summary by Relevant Sections Lawsuit Allegations - The lawsuit claims that MoonLake misrepresented the efficacy of SLK, asserting that its unique Nanobody structure would provide superior clinical outcomes compared to traditional monoclonal antibodies, specifically against the FDA-approved competitor BIMZELX [3][4]. Stock Performance - Following the announcement of the VELA-2 trial results, which failed to meet its primary endpoint and demonstrated inferior efficacy compared to competitors, MoonLake's stock plummeted from $61.99 to $6.24, marking a 90% loss on September 29, 2025 [4]. Investor Actions - Investors who purchased MoonLake stock between March 10, 2024, and September 29, 2025, and experienced significant losses are encouraged to contact Hagens Berman to discuss their legal options and potential appointment as Lead Plaintiff [6][7]. Important Dates - The Lead Plaintiff Deadline for the lawsuit is December 15, 2025, which is rapidly approaching [1][6].

MoonLake, based in Zug, Switzerland, is a clinical-stage biotech firm focused on advancing next-generation immunotherapies. PHILADELPHIA, Dec. 11, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period"). Investor Deadline: Investors who purchased ...

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that during the class period, the defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and has recovered hundreds of millions for investors over the years [4].

Core Points - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding its drug candidate sonelokimab (SLK) [8] - The lawsuit claims that MoonLake promoted SLK as superior to competing drugs while failing to disclose its lack of proven superiority [8] - Following the announcement of disappointing Phase 3 trial results, MoonLake's stock price dropped nearly 90%, resulting in significant investor losses [8] Allegation Details - The lawsuit alleges that MoonLake and its executives misrepresented the clinical advantages of SLK, which was claimed to have a unique Nanobody structure [8] - It is claimed that SLK targeted the same molecules as UCB's BIMZELX, contradicting the company's assertions of superiority [8] - The stock price fell 89.9% on September 29, 2025, after the announcement of the Phase 3 trial results [8] Next Steps - Investors who purchased MoonLake shares between March 10, 2024, and September 29, 2025, are encouraged to contact the law firm for more information and to discuss their legal rights [4] - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is December 15, 2025 [8]

Core Points - The Lead Plaintiff Deadline for the securities class action lawsuit against MoonLake Immunotherapeutics is December 15, 2025 [1] - The lawsuit claims that MoonLake and certain executives made materially false and misleading statements about the clinical prospects of their lead drug candidate, sonelokimab (SLK) [1] - The alleged misleading statements resulted in a significant stock price decline for MoonLake [1]

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics and certain senior executives for potential violations of federal securities laws, with a legal deadline for investors to act by December 15, 2025 [2][4]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [5]. - The company conducted Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa [5]. Allegations and Clinical Data - The lawsuit alleges that MoonLake misrepresented its clinical data and the advantages of SLK's Nanobody structure compared to traditional monoclonal antibody treatments, which may have misled investors regarding the drug's regulatory approval and commercial viability [6][7]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [8].

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that the defendants made false and misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a notable settlement against a Chinese company and significant recoveries for investors in recent years [4].

Core Viewpoint - A class action securities lawsuit has been filed against MoonLake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding MoonLake's drug candidate SLK, asserting that it shares molecular targets with BIMZELX and that SLK's unique Nanobody structure does not provide superior clinical benefits [2]. - Allegations include that SLK's supposed increased tissue penetration does not translate to clinical efficacy, and thus the defendants lacked a reasonable basis for their positive claims about SLK's superiority over monoclonal antibodies [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Legal Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].